Related Experiment Videos
[Immunotherapy in the treatment of cancers]
Abstract:
The recent discovery of the molecular structure of tumor antigens expressed by melanoma cells has contributed to the development of therapeutic strategies aimed at stimulating anti-tumor immunity. The first clinical trials in patients with cancer involved systemic administration of interleukin 2 alone or in combination with alpha-interferon or other chemotherapy agents. Objective clinical responses were observed in 15 to 25% of the patients with melanomas or renal cell cancer. In order to improve these encouraging early results, different clinical protocols are being evaluated with the goal of increasing intra-tumoral concentrations of the administered cytokines. Better optimization of methods for immunizing against specific tumor antigens naturally leads to the transition from non-specific stimulation of the human immune system to tumor antigen specific immunotherapy.
Insights
Researchers are developing new ways to fight cancer by stimulating the immune system. Early trials using cytokines showed promise, and new strategies aim to improve these results for better tumor antigen specific immunotherapy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Context:
- Advances in understanding melanoma tumor antigens enable new therapeutic strategies.
- Early cancer immunotherapy trials utilized systemic interleukin 2 (IL-2) with or without interferon-alpha.
- These initial treatments yielded objective clinical responses in 15-25% of melanoma and renal cell carcinoma patients.
Purpose:
- To enhance anti-tumor immunity by optimizing cytokine delivery.
- To transition from non-specific immune stimulation to tumor antigen-specific immunotherapy.
- To investigate clinical protocols for increasing intra-tumoral cytokine concentrations.
Summary:
- Discovery of melanoma tumor antigen molecular structures facilitates development of novel immunotherapies.
- Systemic administration of interleukin 2 (IL-2) in early trials showed modest clinical responses.
- Current research focuses on improving treatment efficacy by increasing local cytokine levels for targeted anti-tumor responses.
Impact:
- Potential for improved clinical outcomes in cancer patients through enhanced anti-tumor immunity.
- Paving the way for more effective and targeted tumor antigen specific immunotherapies.
- Optimizing cytokine-based therapies may lead to broader applications in treating various cancers.